Latham Advises Invetx in US$25.5 Million Series A Financing

Invetx, a pioneer in protein-based therapeutics for animal health, announced that it has raised an additional US$10.25 million in its Series A financing, bringing the total round size to US$25.5 million. New investors include Casdin Capital and funds managed by Tekla Capital Management, joining existing lead investor Anterra Capital, as well as strategic investors AbCellera Biologics and WuXi Biologics.

Latham & Watkins LLP represented Invetx in the transaction with a corporate team led by Boston/New York partner Kristen Grannis, with Boston associates Spencer Ricks, Peter Prial and Tyler Mills.